Immunohematology/Transfusion Medicine Research Training

提案摘要 该提案是为了更新我们的免疫血液学和输血博士后研究培训补助金 2001年开始的医学。六个职位的计划提供了一个高度组织2-3年的经验 专注的教学法，研讨会，最重要的是，与一个紧张的研究经验， 29位经验丰富、互动性强、资金充足的跨学科导师，代表八个不同的 主要部门。目标是培养富有成效的MD和MD/PhD医生-科学家以及博士 科学家和临床科学家，他们将开始终身从事基础研究， 翻译和临床研究在这个相对代表性不足的领域。认真的职业发展， 个性化的“培训和职业咨询委员会”是该计划的一个标志。两个主要学位- 授予“轨道”也可除了核心博士后计划：一个调查医学 博士学位提供给只希望获得更广泛的研究背景的MD学员， 医学博士/博士学位;以及生物医学工程硕士学位，适用于过去强调基础生物医学的学员 他们希望将诊断和细胞治疗工程维度添加到他们的知识基础中。绘制 从MD，MD/PhD和PhD候选人池集中在那些谁的背景是实验室医学和 病理学（一个人才库，其中始终包括至少10倍以上的优秀，培训补助金合格的候选人， 比可以接受的T32计划），结果是相当积极的。在21名毕业生中， T32项目15年来，平均每位学员发表论文4.2篇，第一作者论文2.2篇 作为T32培训的直接结果，所有21名毕业生都在过去三年中发表了论文 多年来，由于他们不断的科学生涯。所有人都从事科学工作; 48%的人正在争取终身教职 研究型大学的研究密集型职位; 19%的职业生涯在主要的阶梯研究轨道上 大学，21%的人在工业界担任高级科学家职位。“核心”T32是“杠杆”，即 实验室医学系免疫血液学-输血医学研究的全部入组人数 培训计划比T32资助的个人单独约50%，因为延长计划 包括在共享相同基础设施的其他供资机制中的个人。包括在 扩展计划，有63%的大学终身教职，13%的大学研究跟踪教师， 19%在工业界担任高级科学家职位。作为耶鲁唯一的良性血液学T32， 免疫血液学T32在强调博士临床科学家沿着与MD和MD/PhD的国家 医生科学家，也是为数不多的博士后血液学T32，其中包括生物工程和 博士学位轨道，该计划填补了耶鲁大学和全国的重要研究培训需求。

PROPOSAL SUMMARY This proposal is for renewal of our postdoctoral research training grant in Immunohematology and Transfusion Medicine that was initiated in 2001. The six position program provides a highly organized 2-3 year experience of focused dedicated didactics, seminars, and, most importantly, an intense research experience with one of 29 well-established, highly interactive, and well-funded cross-disciplinary mentors representing eight different primary departments. The goal is to generate productive MD and MD/PhD physician- scientists as well as PhD scientists and clinician-scientists, who will be launched on a lifelong investigative career pursuing basic, translational, and clinical research in this relatively underrepresented field. Careful career development by an individualized "Training and Career Advisory Committee" is a hallmark of the program. Two major degree- granting "tracks" are also available in addition to the core post-doctoral program: an Investigative Medicine PhD available to MD-only trainees who wish to obtain a more expansive research background mimicking that of an MD/PhD; and a Masters of Biomedical Engineering for trainees with a past basic biomedicine emphasis who wish to add a diagnostic and cellular therapeutic engineering dimension to their knowledge base. Drawn from an MD, MD/PhD, and PhD candidate pool focused on those whose background is Laboratory Medicine & Pathology (a pool which has always included at least 10 fold more excellent, training grant eligible, candidates than can be accepted into the T32 program), outcomes have been quite positive. Of the 21 graduates of the T32 program over 15 years, there was an average of 4.2 papers and 2.2 first-author papers per trainee published as a direct result of the T32 training and all 21 graduates have published papers in the last three years as a result of their continuing scientific careers. All are in scientific careers; 48% are in tenure-track research-intensive positions at research universities; 19% in careers on the ladder research track at major universities, and 21% are in senior scientist positions in industry. The "core" T32 is "leveraged", that is, the entire enrollment in the Laboratory Medicine Departmental Immunohematology-Transfusion Medicine research training program is greater than the T32-funded individuals alone by about 50%, since the extended program includes individuals on other funding mechanisms sharing the same infrastructure. Including trainees in the extended program, there are 63% University tenure-track faculty, 13% University research track faculty, and 19% in senior scientist positions in industry. As the only benign hematology T32 at Yale, one of the few Immunohematology T32s in the country that emphasizes PhD clinician-scientists along with MD and MD/PhD physician-scientists, and also one of the few postdoctoral hematology T32s that includes bioengineering and PhD degree tracks, this program fills an important research training need both at Yale and nationally.